DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk clinically localised prostate cancer

Brief description of study

The purpose of the study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localized prostate cancer at very high risk of recurrence.


Clinical Study Identifier: s21-00175
ClinicalTrials.gov Identifier: NCT04136353
Principal Investigator: David R. Wise.
Other Investigators: Aaron Edward Katz, Mary K O'Keeffe, Hank Ng, Victor Ricardo Adorno Febles, Thomas B. Daniels, Anthony Corcoran, David Jaihun Byun, Scot Niglio, Andrew J Evans, Maya Dimitrova.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.